Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Famotidine on Telaglenastat PK
NCT04540965Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) comparing Telaglenastat + Famotidine with Telaglenastat + Placebo (2 arms). Primary endpoints: Peak Plasma Concentration at Day 9, Time to peak plasma concentration at Day 9 and 4 more. Started Sep 2020; status: completed.
02
Drugs
telaglenastat
03
Conditions
renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04540965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540965.